We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




RFA Found to Be Best Treatment for Bone Tumor

By HospiMedica staff writers
Posted on 08 Oct 2003
A large-scale study has found that radiofrequency ablation (RFA) should be the treatment of choice for most patients with osteoid osteoma, a benign but painful bone tumor. More...
The finding was reported in the October 2003 issue of Radiology.

The study involved 184 males and 79 females, aged 2-56. Most of the tumors were located in the lower extremities and most of the procedures were for initial treatment. A computed tomography (CT)-guided wire was inserted to the tumor site, which transmitted an electrical current to destroy the lesion. Most patients were able to resume daily activities immediately after the two-hour procedure. Follow-up at 24 months on 126 patients showed that 112 were a complete success, meaning patients had no pain, were taking no medicine, and required no additional procedures. The success rate of repeat treatments was 60%.

In contrast, conventional treatment involves surgery and anti-inflammatory drugs. Open surgery, however, can pose problems. For example, the tumor may be difficult to identify, and incomplete removal could lead to recurrence. Also, cutting out a tumor from a weight-bearing bone might require a prolonged recuperation.

"This study shows that radiofrequency ablation can be performed as an outpatient procedure on the great majority of patients with osteoid osteoma,” said Dr. Daniel Rosenthal, professor of radiology at Harvard Medical School (Boston, USA), who conducted the study. "The success rate is high, the complications rate low, and the recovery brief.”




Related Links:
Harvard Med. School

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.